Quinpramine is a novel compound effective in ameliorating brain autoimmune disease

Mahendra P. Singh; Gerd Meyer zu Hörste; Wei Hu; Anne K. Mausberg; Petra D. Cravens; Todd Eagar; Stefan Löber; Ralf Klingenstein; Peter Gmeiner; Carsten Korth; Bernd C. Kieseier; Olaf Stüve

doi:10.1016/j.expneurol.2008.10.001

Quinpramine is a novel compound effective in ameliorating brain autoimmune disease

Mahendra P. Singh, Gerd Meyer zu Hörste, Wei Hu, Anne K. Mausberg, Petra D. Cravens, Todd Eagar, Stefan Löber, Ralf Klingenstein, Peter Gmeiner, Carsten Korth, Bernd C. Kieseier, Olaf Stüve

Research output: Contribution to journal › Article

11 Scopus citations

Abstract

Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.

Original language	English (US)
Pages (from-to)	397-400
Number of pages	4
Journal	Experimental Neurology
Volume	215
Issue number	2
DOIs	https://doi.org/10.1016/j.expneurol.2008.10.001
State	Published - Feb 2009

ASJC Scopus subject areas

Neurology
Developmental Neuroscience

Access to Document

10.1016/j.expneurol.2008.10.001

Fingerprint Dive into the research topics of 'Quinpramine is a novel compound effective in ameliorating brain autoimmune disease'. Together they form a unique fingerprint.

Cite this

Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. / Singh, Mahendra P.; Hörste, Gerd Meyer zu; Hu, Wei; Mausberg, Anne K.; Cravens, Petra D.; Eagar, Todd; Löber, Stefan; Klingenstein, Ralf; Gmeiner, Peter; Korth, Carsten; Kieseier, Bernd C.; Stüve, Olaf.

In: Experimental Neurology, Vol. 215, No. 2, 02.2009, p. 397-400.

Research output: Contribution to journal › Article

@article{1e23b315ce8c49358422fa8299eb40b6,

title = "Quinpramine is a novel compound effective in ameliorating brain autoimmune disease",

abstract = "Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.",

author = "Singh, {Mahendra P.} and H{\"o}rste, {Gerd Meyer zu} and Wei Hu and Mausberg, {Anne K.} and Cravens, {Petra D.} and Todd Eagar and Stefan L{\"o}ber and Ralf Klingenstein and Peter Gmeiner and Carsten Korth and Kieseier, {Bernd C.} and Olaf St{\"u}ve",

year = "2009",

month = feb,

doi = "10.1016/j.expneurol.2008.10.001",

language = "English (US)",

volume = "215",

pages = "397--400",

journal = "Experimental Neurology",

issn = "0014-4886",

publisher = "Academic Press",

number = "2",

}

TY - JOUR

T1 - Quinpramine is a novel compound effective in ameliorating brain autoimmune disease

AU - Singh, Mahendra P.

AU - Hörste, Gerd Meyer zu

AU - Hu, Wei

AU - Mausberg, Anne K.

AU - Cravens, Petra D.

AU - Eagar, Todd

AU - Löber, Stefan

AU - Klingenstein, Ralf

AU - Gmeiner, Peter

AU - Korth, Carsten

AU - Kieseier, Bernd C.

AU - Stüve, Olaf

PY - 2009/2

Y1 - 2009/2

N2 - Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.

AB - Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.

UR - http://www.scopus.com/inward/record.url?scp=58149481475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149481475&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2008.10.001

DO - 10.1016/j.expneurol.2008.10.001

M3 - Article

C2 - 18996373

AN - SCOPUS:58149481475

VL - 215

SP - 397

EP - 400

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -